Table 2 Baseline characteristics of 14 comparative studies and patients
Authors (year) [Ref] | Study Design | Region | Patients | CPS | BCLC | ECOG | Aetiology | Treatment | Quality Assessment |
|---|---|---|---|---|---|---|---|---|---|
Martin et al. (2010) a [43] | Prospective | several countries | 150 | ST:B = 31% DT:B = 39% | NA | NA | NA | ST, n = 30; DT, n = 120. | 17 |
Kudo et al. (2011) [15] | Phase III Randomized | Japan | 229 | A = 100% | NA | 0 = 87% 1 = 13% | HBV = 20% HCV = 60% | Sorafenib was given 1–3 months after TACE till progression | 18 |
South Korea | |||||||||
Sansonno et al. (2012) [44] | Phase II prospective randomized | Italy | 40 | A = 100% | B = 100% | 0 = 86% 1 = 24% | HCV = 100% | Sorafenib started 1 month after TACE till progression nor unacceptable toxicity | 4 |
Lencioni et al. (2012) a [10] | Phase II prospective randomized | several countries | 307 | A = 100% | B = 100% | 0 = 100% | NA | Continuous sorafenib 3–7d before TACE | 4 |
Qu et al. (2012) [45] | Retrospective | China | 45 | A = 65% B = 35% | B = 35% C = 65% | 0 = 95% 1 = 5% | HBV = 100% | Sorafenib started after TACE | 17 |
Bai et al. (2013) [46] | Prospective | China | 82 | A = 77% B = 23% | B = 23% C = 77% | 0 = 36.5% 1 = 46.5% | HBV = 87.9% HCV = 4.9% | Continuous sorafenib started within 14d after TACE | 19 |
2 = 14.6% | |||||||||
3 = 1.2% | |||||||||
4 = 1.2% | |||||||||
Muhammad et al. (2013) a [47] | Retrospective | USA | 43 | ST:A = 85% DT:A = 77% | A = 46% B = 15% C = 38% | NA | ST:HCV = 69% DT:HCV = 93% | Sorafenib started with 200 mg bid and then increased to 400 mg in the majority of patients | 20 |
Huang et al. (2013) [48] | Prospective | China | 155 | NA | NA | NA | NA | Sorafenib started within 2Â weeks of the first cycle of TACE | 14 |
Hu et al. (2014) [14] | Retrospective | China | 280 | ST:A = 70.7% T:A = 67.7% | B = 100% | NA | ST:HBV = 82.9% T:HBV = 79.8% | Sorafenib after TACE | 20 |
Ohki et al. (2015) [6] | Retrospective | Japan | 95 | ST:A = 70.8% T:A = 56.3% | NA | NA | ST:HCV = 75.0% T:HCV = 67.6% | Sorafenib was started within 2 weeks after TACE | 17 |
Yao et al. (2016) [12] | Prospective | China | 150 | A = 84% B = 16% | B = 42% C = 58% | 0 = 42% 1 = 58% | ST:HBV = 84% T:HBV = 83% | Sorafenib therapy was initiated within 1 week before or after the initial TACE treatment | 20 |
Zhang et al. (2016) [49] | Retrospective | China | 20 | A = 100% | NA | 0 = 85% 1 = 15% | HBV = 80% | Sorafenib was given with an interval of 4-7 days before or after TACE session | 19 |
Wan et al. (2016) [50] | Retrospective | China | 450 | A = 87% B = 13% | NA | 0–1 = 91% 2 = 9% | NA | Oral sorafenib was administrated before or after TACE | 14 |
Varghese et al. (2017) [13] | Retrospective | India | 124 | B:A = 55.9% B = 44.1% C:A = 46.2% B = 53.8% | B = 47.6% C = 52.4% | NA | B:HBV = 37.3% HCV = 18.7% C:HBV = 26.2% HCV = 23% | Sorafenib was introduced 5d after TACE | 17 |